Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 -1.34%75 Debt-to-Equity is 2.05 as of Jun. 2026, which is 220% above its 10-year median of 0.64. GuruFocus rates TPE:1795 with a GF Score™ of 75/100 and a GF Value™ of NT$459.23 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks worse than 95.07% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lotus Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
TPE:1795'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29 Med: 0.64 Max: 2.05
Current: 2.05
During the past 13 years, the highest Debt-to-Equity Ratio of Lotus Pharmaceutical Co was 2.05. The lowest was 0.29. And the median was 0.64.
TPE:1795's Debt-to-Equity is ranked worse than 95.07% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TPE:1795: 2.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lotus Pharmaceutical Co Debt-to-Equity Related Terms
Lotus Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a Debt-to-Equity of 2.05 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lotus Pharmaceutical Co and its competitors. This is 220% above median its historical median of 0.64. Over the past decade, Lotus Pharmaceutical Co's Debt-to-Equity has ranged from 0.29 to 2.05. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #771 out of 811 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is Lotus Pharmaceutical Co's Debt-to-Equity too high?
Lotus Pharmaceutical Co's current Debt-to-Equity of 2.05 is 220% above median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 2.05. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Lotus Pharmaceutical Co's value of 2.05 is 632.1% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #771 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #771 out of 811 companies for Debt-to-Equity. This places Lotus Pharmaceutical Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Lotus Pharmaceutical Co's value of 2.05 is 632.1% above this benchmark. Historically, Lotus Pharmaceutical Co's own Debt-to-Equity has ranged from 0.29 to 2.05 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 0.28, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current Debt-to-Equity of 2.05 is 632.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current Debt-to-Equity is 2.05, which is 220% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$459.23, compared to a current price of NT$184.00 — trading 59.9% below its estimated fair value. The current Debt-to-Equity is 2.05, which is 220% above median its 10-year median of 0.64 and 632.1% above the Drug Manufacturers industry median of 0.28. Lotus Pharmaceutical Co's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Debt-to-Equity is 2.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$184.00 is trading 59.9% below its estimated GF Value™ of NT$459.23.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
Debt-to-Equity: 2.05 (220% above median its 10-year median of 0.64)
GF Value™: NT$459.23 vs. price of NT$184.00 (59.9% below fair value)
Industry Position: 632.1% above the Drug Manufacturers median (#771 of 811)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
75GF Score
Get the complete analysis for TPE:1795
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
